The much-awaited 2024 NYC Neuromodulation Conference, held from July 31- August 4 2024, featured Magnus Medical’s presentation of new clinical outcomes of their innovative SAINT TMS Therapy. The conference featured interactive sessions, panels, and social events.
This conference held at the City College of New York brought together hundreds of scientists, technologists, doctors, and clinicians together in a dynamic oriented program. The main aim was to discuss the newest breakthroughs in neurotechnology and neuromodulation.
The NYC Neuromodulation Conference has become one of the leading events of this kind, and the theme for the current year’s conference was “Optimized interventions are personalized interventions” which makes it apparent that the methods applied in neuromodulation are not a one-size-fits-all type.
Attendees received numerous opportunities for meetings and interactions with other participants, which included poster sessions, social activities, and panels with funders and investors for the purpose of new partnership formation and stimulation of new and ongoing projects. Pre and post conference workshops included:
- Addiction Neuromodulations Trials Workshop
- Computational Neuromodulation Workshop
- Fundamentals and Applications of tDCS Hands-on Workshop
- NYC Clinical & Research TMS Course
The SAINT treatment machine uses rapid-acting repetitive transcranial magnetic stimulation to produce high remission rates in patients with treatment-resistant depression.
One of the main focuses of the conference was the SAINT Therapy by Magnus Medical, and the company shared new clinical data about the effectiveness of the treatment for various neurological disorders.
With collaboration with Magnus Medical, Kaizen Brain Center remains at the forefront of neurotechnology and neuromodulation. These principles were well demonstrated through our pursuit of new neurodegenerative disease therapies and the betterment of patient care.
An Open Label Pilot Trial to Assess the Feasibility of Using the Magnus Neuromodulation System with Stanford Accelerated Intelligent Neuromodulation Therapy (SAINTⓇ) as a Personalized Continuation Therapy for Depression sought to evaluate an optimized continuation therapy regimen for TRD. Twenty-one participants entered remission the week following treatment with SAINT and were enrolled in this study.